Skip to main content

Table 2 Number of tuberculosis episodes and time to tuberculosis disease, by individual biologic therapy

From: Incident tuberculosis disease in patients receiving biologic therapies in the Western Cape, South Africa from 2007 to 2018

Biologic therapies

Total no of patients treateda

No of TB episodes b (% of TB episodes/ total treated) c

Time to TB (months) d Median (IQR)

All biologics

41

8.30 (3.67–27.70)

TNF-α inhibitors

209

20

18.95 (5.08–32.79)

 

adalimumab

48

4 (8.3%)

12.56 (3.20–18.90)

 

etanercept

49

3 (6.1%)

33.84 (12.59–46.82)

 

golimumab

12

2 (16.7%)

4.82 (4.33–5.31)

 

infliximab

100

11 (11.0%)

27.70 (3.64–39.02)

Non-TNF-α inhibitors

441

21

7.43 (2.83–16.24)

 

abatacept

4

0

 

rituximab

418

20 (4.8%)

7.08 (2.48–18.02)

 

tocilizumab

18

1 (5.6%)

15.02 (15.02–15.02)

 

ustekinumab

1

0

  1. atotal number of patients exposed to a biologic therapy at any point in study period (one patient may be exposed to multiple biologic therapies)
  2. bnumber of tuberculosis episodes (single or multiple) per patient according to the most recent biologic therapy used before or at the time of tuberculosis disease diagnosis (n = 41).
  3. cpercentage of tuberculosis disease episodes (based on most recent biologic therapy used) per total number of patients exposed to a biologic therapy.
  4. dtime to tuberculosis disease in months from the start of the most recent or current biologic used to the date of tuberculosis disease diagnosis.
  5. TB tuberculosis, TNF-α tumour necrosis factor-alpha, min minimum, max maximum, IQR interquartile range